NCT05784935

Brief Summary

To conduct an single blinded, non-randomized, prospective, single center trial to validate the performance of a novel state-of-the-art Artificial Intelligence model (AI-Model) for colorectal lesion detection during routine diagnostic colonoscopy and to evaluate its feasibility in daily endoscopy. Consecutive patients referred for a screening, surveillance or diagnostic colonoscopy will be included

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
380

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 13, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

March 20, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 27, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2023

Completed
Last Updated

January 27, 2025

Status Verified

November 1, 2023

Enrollment Period

3 months

First QC Date

November 13, 2022

Last Update Submit

January 23, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Performance of a novel state-of-the-art Artificial Intelligence model (AI-Model) for colorectal lesion detection during routine diagnostic colonoscopy

    A single-blinded, non-randomized prospective trial to validate the performance of a novel state-of-the-art Artificial Intelligence model (AI-Model) for colorectal lesion detection during routine diagnostic colonoscopy.

    1 Year

Interventions

Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result

Eligibility Criteria

Age19 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Our pilot series showed AI assistance can detect up to 80 % of missed lesions with sample variance at around 0.032. We hypothesize that the adenoma/polyp miss rate of conventional colonoscopy can be reduced by 50% to 75% with AI assistance. Assuming 4% patients may be excluded. The sample size is estimated to be 381 patients in total with a power of 95% and a significance level of 0.05. An interim analysis will be performed when the first 150 patients are recruited to verify the sample size estimation

You may qualify if:

  • Patients undergoing colonoscopy of age 18 to 80 years.
  • Consecutive adult patients scheduled to undergo routine colonoscopy at AIG

You may not qualify if:

  • Females who are pregnant
  • Patients who are unsuitable for any other reason to participate in the study in the opinion of the investigator
  • Recent colonoscopy within past 12 month
  • History of inflammatory bowel disease
  • History of colorectal cancer
  • Previous bowel resection (apart from appendectomy)
  • Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes
  • Bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AIG Hospitals

Hyderabad, Telangana, 500032, India

Location

MeSH Terms

Conditions

Colonic Polyps

Condition Hierarchy (Ancestors)

Intestinal PolypsPolypsPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Hardik Rughwani, MD, DM

    Asian Institute of Gastroenterology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 13, 2022

First Posted

March 27, 2023

Study Start

March 20, 2023

Primary Completion

July 1, 2023

Study Completion

November 1, 2023

Last Updated

January 27, 2025

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations